Alector Inc (NAS:ALEC)
$ 1.78 -0.04 (-2.2%) Market Cap: 174.32 Mil Enterprise Value: -244.33 Mil PE Ratio: 0 PB Ratio: 1.47 GF Score: 50/100

Alector Inc to Discuss Collaboration with GlaxoSmithKline PLC for AL001 & AL101 Call Transcript

Jul 02, 2021 / 12:30PM GMT
Release Date Price: $35.21 (+57.12%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the conference call being hosted today by Alector's management. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Michelle Corral. Please go ahead, ma'am.

Michelle Corral
Alector, Inc. - VP of Communications & IR

Thank you, Sarah. Good morning, and thank you all for joining us on today's call. I'm Michelle Corral, Alector's Vice President, Communications and Investor Relations. Today, we are excited to be sharing the details of a collaboration with GlaxoSmithKline to jointly develop and commercialize our progranulin franchise programs, AL001 and AL101. A press release detailing the terms of this collaboration was issued earlier today and is available on our website.

Leading today's call is Alector's CEO and Co-Founder, Dr. Arnon Rosenthal. Arnon is joined today by Dr. Shehnaaz Suliman, Alector's President and Chief Operating Officer. Following their prepared

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot